Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study
暂无分享,去创建一个
J. McCaffrey | P. Kelly | R. McDermott | J. Feeney | A. Baird | M. Lim | S. Finn | J. Greene | P. Thirion | I. Parker | A. Teiserskiene | Helen Matthews | Sylva Helanova | Olwyn Deignan
[1] F. Saad,et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. , 2020, European urology.
[2] F. Saad,et al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer , 2020, Prostate Cancer and Prostatic Diseases.
[3] D. Santini,et al. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. , 2020, Critical reviews in oncology/hematology.
[4] M. Morris,et al. Radium-223 mechanism of action: implications for use in treatment combinations , 2019, Nature Reviews Urology.
[5] M. Stockler,et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.
[6] Clemens Grassberger,et al. Assessing the interactions between radiotherapy and antitumour immunity , 2019, Nature Reviews Clinical Oncology.
[7] L. Collette,et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. , 2019, Journal of Clinical Oncology.
[8] E. Antonarakis,et al. Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. , 2019, Translational andrology and urology.
[9] F. Saad,et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[10] A. Formenti,et al. Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit. , 2019, European urology.
[11] O. Sartor,et al. Metastatic Prostate Cancer. , 2018, The New England journal of medicine.
[12] A. Iagaru,et al. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. , 2018, The oncologist.
[13] H. Scher,et al. Maintaining Bone Health During Hormonal Therapy for Prostate Cancer , 2017, Annals of Internal Medicine.
[14] R. Vessella,et al. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models , 2017, Clinical Cancer Research.
[15] F. Saad,et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. , 2017, European urology.
[16] F. Saad,et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. , 2016, The Lancet. Oncology.
[17] A. Armstrong,et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] V. Arora,et al. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.
[19] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[20] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[21] J. Humm,et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.
[22] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Nilsson,et al. High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? , 2006, Clinical Cancer Research.
[24] C. Pashos,et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Henriksen,et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. , 2002, Cancer research.
[26] F. Saad,et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy , 2014 .
[27] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.